A Phase I, Open Label, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Intramuscular Injections of Letrozole LEBE at Different Strengths in Voluntary Healthy Post-Menopausal Women
Latest Information Update: 12 Feb 2025
At a glance
- Drugs Letrozole (Primary)
- Indications Breast cancer
- Focus Pharmacokinetics
- Acronyms LIELA-1
- Sponsors Rovi
Most Recent Events
- 10 Feb 2025 Planned End Date changed from 1 Jan 2025 to 1 Jun 2025.
- 10 Feb 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Jun 2025.
- 10 Feb 2025 Status changed from recruiting to active, no longer recruiting.